Skip to main content
User Image

Shaik Sarfaraz Nawaz

Researcher

Researcher

كلية الطب
Strategic Center for Diabetes Research, College of Medicine, King Saud University

Serum Sex Hormone Binding Globulin (SHBG) Relation with Different Components of Metabolic Syndrome in Men with Type 2 Diabetes.

, Siddiqui K, Al-Rubeaan K, Nawaz SS, Aburisheh KH, Alaabdin AMZ, Tolba IA. . 2018

Sex hormone binding globulin (SHBG) is demonstrated to be decreased in subjects with metabolic syndrome (MetS). The aim of the present study was to investigate the association of SHBG in relation to MetS components among men with type 2 diabetes (T2D). This cross-sectional study was carried out among 429 Saudi T2D male patients aged >30 years. Metabolic syndrome was defined using International Diabetes Federation (IDF) criteria. Fasting blood glucose (FBG), HbA1c, albumin, and lipid parameter were measured. Gonadal hormones, namely total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and SHBG were determined using ELISA. The SHBG levels of the MetS group was significantly lower than non-MetS group 47.25±31.03 nmol/l vs. 56.55±37.84 nmol/l; p=0.013. As the MetS score increases, SHBG and HDL levels decrease while weight, BMI, waist circumference, SBP, DBP, FBG, HbA1c, TC, and TG levels increase. SHBG correlated with age, BMI, TG, HDL, TT, free testosterone, and bio-available testosterone. This is the first study that provides detailed analyses of SHBG with MetS components in male diabetic subjects. The mean serum SHBG levels gradually declined with the addition of MetS components in T2D men. TT, free testosterone, and bio-available testosterone remained independently associated with SHBG by multivariable regression analysis.

Publication Work Type
Original Research
Volume Number
50
Magazine \ Newspaper
Horm Metab Res.
Pages
138-144
more of publication
publications

Abstract

by K Siddiqui, TP George, SS Joy, SS Nawaz,
2020
Published in:
The Journal of Maternal-Fetal & Neonatal Medicine
publications

Metabolomics is rapidly evolving omics technology in personalized medicine, it offers a new avenue for identification of multiple novel metabolic mediators of impaired glucose tolerance and…

by S Chowdhury, SM Faheem, SS Nawaz, K Siddiqui,
2021
Published in:
Personalized Medicine